ROS1 and non-small cell lung carcinoma: Supported by multicenter retrospective analyses and prospective trials, crizotinib has received regulatory approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China’s National Medical Products Administration (NMPA) as first-line standard therapy for advanced ROS1 fusion-positive NSCLC.